Premature ovarian failure and tissue engineering

J Cell Physiol. 2020 May;235(5):4217-4226. doi: 10.1002/jcp.29376. Epub 2019 Oct 29.

Abstract

Premature ovarian failure (POF) usually happens former to the age of 40 and affects the female physiological state premenopausal period. In this condition, ovaries stop working long before the expected menopausal time. Of diagnostic symptoms of the disease, one can mention amenorrhea and hypoestrogenism. The cause of POF in most cases is idiopathic; however, cancer therapy may also cause POF. Commonly utilized therapies such as hormone therapy, in-vitro activation, and regenerative medicine are the most well-known treatments for POF. Hence, these therapies may be associated with some complications. The aim of the present study is to discuss the beneficial effects of tissue engineering for fertility rehabilitation in patients with POF as a newly emerging therapy.

Keywords: cell therapy; premature ovarian failure; regenerative medicine; scaffold; stem cell; tissue engineering.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Female
  • Humans
  • Pluripotent Stem Cells
  • Primary Ovarian Insufficiency / therapy*
  • Tissue Engineering / methods*